1.Regulation of cyclin E and cancers
Journal of International Oncology 2012;39(5):337-340
Cyclin E is expressed starting from the middle G1 phase of the cell cycle,and is accumulated in the G1/S boundry.Cyclin E binds to and activates the cyclin-dependent kinase CDK2.Cyclin E-CDK2 complex initiates a cascade of events that leads to DNA replication by phosphorylating its substrates,such as Rb,CDC6,NPAT and P107,etc.Additionally,cyclin E plays an important role in the regulation of genomic stability,spindle-organizing structure and centrosome cycle.Cyclin E expression is trans-activated by members of the transcription factor E2F family and degrades via the ubiquitin-proteasome pathway.At the same time,it is also negatively regulated by the CIP/KIP proteins.Cyclin E highly expressed in the initiation and progression of different human cancers,such as breast cancers,lung cancers,leukemia,lymphomas and others.
2.p21 activated kinase 4 and tumor
Journal of International Oncology 2012;39(1):15-18
p21 activated kinase 4 (PAK4) is a member of a family of serine/threonine kinase.PAK4plays an important role in a variety of cellular functions including cell cycle,cell proliferation,apoptosis,and cytoskeletal reorganization.Recently,PAK4 has been shown to overexpress in a variety of malignancies,and contribute to cancer cell migration and invasion through multiple signalling pathways.
3.A Study of Wrong Initial Pronunciation of Children with Cochlear Implants
Journal of Audiology and Speech Pathology 2017;25(1):66-69
Objective To study the effects of pronunciation after cochlear implantation in children,and find out the common rules of initials consonant pronunciation errors.Methods We used the cards as the pronunciation articulation test from hearing impairment children's hearing,language competency assessment standards and methods to evaluate auditory-verbal ability after cochlear implantation,then recorded and analyzed the errors of the initials consonant.Results After training for 10 months,we evaluated speech articulation of prelingually deaf children of 3 to 5 years old with cochlear implants 73.93%±12.76%.The most incorrect pronunciations were/s/,/z/,/sh/,/g/,/ch/,/j/,/k/,/l/,/c/,/zh/,/f/and/p/,which had resulted in substitution.According to the classification of pronunciation articulation,it focused on supradialectical and velar while the least in bilabial and blade-alveolar.Ac-cording to the classification of pronunciation method,nasal,lateral and unaspirated stop had low error rates.Conclu-sion Only do when we comprehend rules of cochlear implants in children pronunciation as well as study,can we solve problems and do well in language training.The most incorrect pronunciations in children with CI are supradia-lectical and velar,the language training should be performed aecordingly.
4.Application of optical molecular imaging for the development of anticancer drugs
Journal of International Oncology 2011;38(6):432-435
Optical molecular imaging call non-invasively, quantitatively, real-time and dynamically monitor the biological processes in vivo, and enhance the understanding of disease and drug activity in the drug development process, which has been effectively used for target identification, compounds screening. pharmacodynamic action, pharmacokinetics research and evaluation of drug effect.
5.Resistant mechanisms of doxorubicin
Journal of International Oncology 2013;40(12):886-889
Doxorubicin is widely used in chemotherapy of breast cancer and many other cancers.How ever,doxorubicin resistance restricts its use to some extent.The mechanisms of doxorubicin resistance may involve transport protein,apoptosis protein,DNA repair function,enzyme and other factors.Researches about reversing doxorubicin resistance are ongoing and provide some effective therapeutic regimens to overcome doxorubicin resistance clinically.But the specific mechanism of doxorubicin resistance is yet to be elucidated.It is expected that more reasonable and effective counter-measures will be put forward to improve the theraputical effect of doxorubicin.
6.Reveal of the 374th Clause of Treatise on Febrile Disease
Journal of Zhejiang Chinese Medical University 2017;41(8):658-660
[bjective]This paper is about to expound the true meaning of the 374th clause of Treatise on Febrile Diseases. [Methods] Under the guidance of dynamic thinking of Treatise on Febrile Diseases, with the help of other clauses about Zaoshi syndrome, Small Decoction for Ordering the Qi, Gardenia and Prepared Soybean Decoction, to understand the 374th clause.[Results] The 374th clause is not alone, it should be combined with the 375th clause, they tell us when we treat the combination of Shi and Re syndrome of Yangming disease, we should use Small Decoction for Ordering the Qi first, then use Gardenia and Prepared Soybean Decoction. At the same time if we want to understand the 374th clause, we should combine it with the 368th clause to 375th clause, it tells us the treatment and difference between the diarrhea of cold, wet heat, Shi and Re, deficient heat etc. [Conclusion]This clause institutes the principle of the treatment for Shi and Re syndrome of Yangming disease, completing the system of treating diarrhea. It also tells us how to combine two decoctions.
7.Molecular targeted therapy for breast cancer patients based on Notch signal transduction pathway
Yongqu ZHANG ; Xiaowei DOU ; Guojun ZHANG
Journal of International Oncology 2013;40(9):678-680
Studies show that the Notch signal transduction pathway involves in the regulation and control of cell proliferation,differentiation and apoptosis.Aberrant Notch signaling transduction pathway can induce breast cancer in transgenic mice.High expressions of either Notch receptors or their ligands have been linked to poor prognosis in patients with breast cancer.Inhibition of Notch signal transduction pathway may be beneficial for breast cancer treatment.
8.Targeted therapy for triple-negative breast cancer
Ronghui LI ; Caiwen DU ; Guojun ZHANG
Journal of International Oncology 2012;39(7):519-522
Triple-negative breast cancer(TNBC)is a special subtype of breast cancer which is invalid to endocrine therapy.Anti-Her2 targeted therapies such as herceptin and lapatinib are not suitable to TNBC.At present,conventional chemotherapy is the only way for the medical therapy of TNBC.Thus,searching for novel therapeutic agents for TNBC is one of hot researches of breast cancer.New targeted therapy drugs such as PARP-1 inhibitors,EGFR inhibitors,CXCR4 inhibitors,anti-angiogenesis drugs,Src tyrosine kinase inhibitor,and mTOR inhibitor are being researched.
9.Study on management mode of antiepileptic drugs following epilepsy surgery
Guojun ZHANG ; Xiaolian QI ; Yuping WANG
Chinese Journal of Neurology 2008;41(6):400-403
Objective To investigate antiepileptic drug application and the influential factors in patients after epilepsy surgery.Methods During the period from 2002 through 2005,170 patients with intractable epilepsy who received epilepsy surgery in Xuanwu hospital were studied.They were divided into 3 groups according to the stages of operation.Patients in group A received epilepsy surgery during 2002 to October 2003,those in group B received initial phannacentieal care after epilepsy surgery during November 2003 to October 2004,and those in group C received integrated pharmaceutical care after epilepsy surgery during November 2004 to October 2005.The clinical outcomes,factors affecting antiepileptic drugs,safety and compliance with antiepileptic medication were analyzed.Results Patient's clinical outcomes(group B was 71%and group C was 81%),safety and compliance with antiepileptic medication in group B and group C are better than those in group A(46%)with a significance difference(X2=7.08,15.50,P<0.05).Conclusions The integrated pharmaceutical care rendered from the cooperation of neurosurgeon,neurologist and clinical pharmaceutist is a new and effective management mode for postsurgical epilepsy patients.
10.Role of CXCR4 expression in progress and prognosis of breast cancer
Hongwu CHEN ; Guoying WU ; Guojun ZHANG
Journal of International Oncology 2011;38(1):36-38
CXCR4, a receptor for stromal cell-derived factor-1 (SDF-1, also know as CXCL12) and a member of the chemokine receptor family, has been shown to play an important role in the proliferation, migration, invasion and metastasis of breast cancer cells. CXCR4 expression is an early event in breast cancer development and may serve as a biomarker for early detection and diagnosis of breast cancer. Expression of CXCR4 has been demonstrated to correlate with metastasis and poor prognosis in breast cancer. Inhibition of CXCR4 expression may be a potential target of breast cancer treatment.